Edition:
United Kingdom

GlaxoSmithKline PLC (GSK.L)

GSK.L on London Stock Exchange

1,308.60GBp
19 Feb 2018
Change (% chg)

-10.00 (-0.76%)
Prev Close
1,318.60
Open
1,324.00
Day's High
1,324.60
Day's Low
1,303.80
Volume
4,353,589
Avg. Vol
11,067,242
52-wk High
1,724.50
52-wk Low
1,235.20

Chart for

About

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare... (more)

Overall

Beta: 1.21
Market Cap(Mil.): £75,181.28
Shares Outstanding(Mil.): 4,918.63
Dividend: 19.00
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.64
EPS (TTM): -- -- --
ROI: -- 14.90 10.66
ROE: -- 16.41 14.30

BRIEF-Glaxosmithkline ‍Receives European Approval For Expanded Indication For Fluarix Tetra For Ages Six Months And Older​

* ‍RECEIVES EUROPEAN APPROVAL FOR EXPANDED INDICATION FOR FLUARIX TETRA (INFLUENZA VACCINE) FOR AGES SIX MONTHS AND OLDER​ Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

15 Feb 2018

BRIEF-Glaxosmithkline Submits Landmark Impact Data To European Medicines Agency To Support Expanded Label For Trelegy Ellipta​

* ‍GSK SUBMITS LANDMARK IMPACT DATA TO EUROPEAN MEDICINES AGENCY TO SUPPORT EXPANDED LABEL FOR TRELEGY ELLIPTA​ Source text for Eikon: Further company coverage: (bangalore.newsroom@thomsonreuters.com)

14 Feb 2018

Drug company Innoviva settles with activist hedge fund Sarissa: sources

U.S. respiratory drug company Innoviva Inc has reached a settlement with activist hedge fund Sarissa Capital Management LP to replace its board of directors and remove the threat of a new proxy contest, people familiar with the matter said on Monday.

13 Feb 2018

Drug company Innoviva settles with activist hedge fund Sarissa -sources

Feb 12 U.S. respiratory drug company Innoviva Inc has reached a settlement with activist hedge fund Sarissa Capital Management LP to replace its board of directors and remove the threat of a new proxy contest, people familiar with the matter said on Monday.

13 Feb 2018

BRIEF-GlaxoSmithKline Says ‍ViiV Healthcare Launches New Two-Drug HIV Study

* ‍VIIV HEALTHCARE LAUNCHES EIGHTH PHASE III STUDY IN TWO-DRUG REGIMEN PROGRAMME FOR HIV-1 TREATMENT​

08 Feb 2018

BRIEF-GSK's ViiV Healthcare Says Filed Patent Infringement Litigation Against Gilead Sciences

* GLAXOSMITHKLINE PLC - VIIV ‍ANNOUNCED IT FILED PATENT INFRINGEMENT LITIGATION AGAINST GILEAD SCIENCES INC. OVER BICTEGRAVIR IN UNITED STATES AND CANADA​ Source text for Eikon: Further company coverage:

08 Feb 2018

GlaxoSmithKline sees light at end of Advair tunnel

LONDON GlaxoSmithKline sees growth strengthening over the next few years as the drugmaker weathers increased competition in its core respiratory and HIV businesses that could cause earnings to dip this year.

07 Feb 2018

GlaxoSmithKline sees light at end of Advair tunnel

LONDON GlaxoSmithKline sees growth strengthening over the next few years as the drugmaker weathers increased competition in its core respiratory and HIV businesses that could cause earnings to dip this year.

07 Feb 2018

UPDATE 2-GlaxoSmithKline sees light at end of Advair tunnel

* CEO says Pfizer consumer business "not a need to have" (Adds further CEO comments, analyst and investor reaction)

07 Feb 2018

BRIEF-GSK Says Bexsero Gets Breakthrough Therapy Designation From U.S. FDA​

* GSK-BEXSERO GETS BREAKTHROUGH THERAPY DESIGNATION FROM FDA FOR PREVENTION OF INVASIVE MENINGOCOCCAL DISEASE IN CHILDREN AGED 2-10 YRS ​ Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 80 6749 1136)

07 Feb 2018

Earnings vs. Estimates